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INNOVATIVE TECHNOLOGIES : FACTORS INFLUENCING FINANCING DECISIONS
IN ITALIAN HOSPITALS
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Innovative PCR tests for rapid and accurate diagnosis of infections represent a
challenge for laboratory budgets. Some laboratory managers have been more suc-
cessful than others to obtain funding for novel technologies for which no tariffs
exist. OBJECTIVES: This project aimed to understand critical issues of the funding
and purchasing process as well as key factors for positive funding decisions to
introduce molecular technologies in Italy. METHODS: We conducted a 2-phase
health care use project. Phase 1 included a landscape analysis, stakeholder map-
ping and interviews with non-users and users of molecular assays. Phase 2 con-
sisted of a workshop with key players involved at various levels in the funding and
purchase decision process. RESULTS: Successful microbiologists have succeeded
in transferring the understanding of the innovative technique’s value for the hos-
pital to the Strategic Direction. Directors of Microbiology of Complex Units, and/or
with the process of reorganization of Laboratory Medicine Departments com-
pleted, have more decision power and are expected to introduce innovative diag-
nostics. The Federation of Regional Superintendents and Treasurers of Health
(FARE) plays an important role in the request/tender process. The non-inclusion of
a new diagnostic test in the Tariff Nomenclature is not a major obstacle in the
decision making process as new techniques can be adopted by “assimilation”. The
Italian health care system is characterized by its regionalization. Policies and pri-
orities of introduction, funding and purchasing of new diagnostic technologies for
Regional Health Plans and Health Funds differ greatly. CONCLUSIONS: The deci-
sion to introduce innovative technologies must be aligned with the objectives of
the respective Regional Health Plans. Through rapid and accurate diagnosis, PCR
tests improve patient management. The case needs to be made to the Strategic
Direction of hospitals, to the Superintendents managing the request process, and
reinforced with future prospective studies.
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OBJECTIVES: Promotion of generic drug utilization to reduce patient’s out-of-
pocket costs and improve insurance finance is a cross-national policy. The share of
generics in Japan, 8.6% on a value basis, is lower than in other OECD countries.
Although safety concerns, inventory management, drug charge margins and pa-
tient/physician brand preferences are cited as restraints to adoption of generic
drugs prescriptions, their price-setting remains to be studied empirically. The pur-
pose of this study is to verify the effects of price markups/levels of generic drugs on
their prescription in hospitals under Diagnosis-Procedure-Combination (DPC)
based payment system considered unaffected by drug charge margins and wherein
prescription of the lowest-priced generic drugs is economically rational.
METHODS: A retrospective cohort study of inpatients with drug prescriptions for
which generic drug is already marketed. 732 drugs of 20 categories from among
calcium channel blockers, gastric secretion inhibitors, antibacterial drugs, hEPOs,
cancer drugs and radiocontrast agents were included. Data were collected from 980
acute care hospitals in Japan during April 1, 2010 to March 31, 2011. RESULTS: A
total of 2,768,456 (54.9%) among the study population of 5,041,157 cases were ana-
lyzed. An average of six price ranges existed for each dosage form of each drug, and
price variability, such as 89 price ranges in total for calcium channel blockers, was
found. Even after adjusting for other covariates, the share of prescriptions of the
highest-priced generic drugs was the greatest among the price ranges of generic
drug. CONCLUSIONS: Physician prescription was nearly uninfluenced by markups.
Out results suggest that positive financial effects on medical insurance may result
from lowering prices of generic drug in the highest price range rather than by
aggregating those in the lowest range.
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OBJECTIVES:A former study indicated that clinical trial related activities generated
250-300 million USD revenue in 2008 for Hungarian health care providers and clin-
ical research organizations, and so 0.15% of the Hungarian GDP was attributable to
clinical trials. The purpose of this study was to measure the total annual value of
investigational medical products (IMPs) provided by sponsors in clinical trials in
Hungary. METHODS: All phase II-IV trials licensed in Hungary in 2010 were se-
lected to assess value of IMPs due to savings from free supply of drugs for patients
treated in clincal trials. Phase I and bioequivalence studies were excluded since
participants are healthy volunteers without need for treatment. We retrieved the
following data from clinical trial master files at the Directorate General of National
Institute of Pharmacy: EudraCT number, full title of the trial, therapeutic area,
interventions, length of treatment, product names, number of treatment arms in
the trial, planned number of study participants in Hungary, study design, clinical
trial authorisation date. Drug prices were estimated based on the price of compar-
ator or similar drugs in the same therapeutic area. 290 HUF/Euro exchange rate was
applied. RESULTS: The estimated annual value of IMPs in phase II-IV clinical trials
was 29 million € in Hungary in 2010. Phase III. trials contributed by 65% to the total
amount, while phase II and phase IV trials added 15% and 20%. The value of IMPs
depended on the therapeutic area. CONCLUSIONS: Significant savings could be
generated from avoided drug costs for clinical trial participants, the value of IMPs
was equal with 2,5% of the public pharmaceutical budget (1,18 billion €) by the
National Health Insurance Fund. Our study confirms a neglected economic benefit
of clinical trials.
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UNDERSTANDING ACCESSIBILITY FOR NEW MEDICINES ENTERING THE
MARKET SINCE 2007 IN PORTUGAL USING SURVIVAL ANALYSIS
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OBJECTIVES: In public funded health care systems accessibility (time to decision)
to new medicines is crucially dependent on the assessment process by the compe-
tent Authorities. In Portugal, since 2007, new medicines are explicitly (hospital) or
implicitly (ambulatory) assessed (cost and effectiveness) by the Portuguese Minis-
try of Health (PMH) before they can be purchased (financed) by hospitals or Re-
gional Health Authorities, respectively. This study aimed to measure time to fi-
nancing decision from the PMH using survival analysis and confront the results to
the maximum decision timelines established in the Law: 70 days (hospital) and 110
days (ambulatory). METHODS: A questionnaire was designed to collect data from
the pharmaceutical companies submitting reimbursement applications of new
medicines or medicines with new therapeutic indications (NMNTI) to the PMH
between January 2007 and June 2011. A total of 119 NMNTI were analyzed using the
Turnbull non-parametric estimator and Accelerated Failure Time regression mod-
els with Gaussian mixture distributions allowing for interval, left and right censor-
ing. Model selection was conducted by backward stepwise elimination based on
Akaike’s Information Criterion. RESULTS: Median time from application to PMH
decision was 292 days (95%CI: 270-336) in ambulatory and 481 days (95%CI: 398-819)
in hospital medicines. Evidence was found that these decision times were signifi-
cantly (p0.001) increased when the therapeutic value assessment was based on
expert panels (63%), multiple comparators (22%) and Oxford CEBM level of evidence
less than 1A (19%); and economic value assessment was relative to cardiovascular
(58%) or immunomodulatory non-oncology medicines (44%) and included an eco-
nomic evaluation study proactively provided by pharmaceutical companies (37%)
or enforced by the PMH (103%). CONCLUSIONS: Adequate survival analysis is use-
ful to understand accessibility to new medicines or medicines with new therapeu-
tic indications. Furthermore, substantial problems were found in the accessibility
to these medicines in Portugal since 2007.
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OBJECTIVES: Public funding of medicines is a key health policy instrument for
governments in virtually all countries in the world. Given the typical requirement
of a prior assessment, the decisions of health authorities, and the speed with which
they are taken, are critical determinants in the accessibility to medicines with new
molecules or therapeutic indications. This research has as a principle objective the
use of extreme value statistics in assessing the probability of long decision times
associated with public funding requests of medicines in Portugal. METHODS: The
time to final decision on public funding for 119 medicines with market authoriza-
tion between January of 2007 and June of 2011 was analyzed using an adaptation of
the semi-parametric Peaks-Over-Threshold maximum likelihood methodology for
censored survival data. The methodology assumes that for the majority of distri-
butions, conditional on certain theoretical arguments common to extreme value
statistics, excesses over a suitable large threshold can be modeled with a General-
ized Pareto distribution. RESULTS: A non-negligible probability of 6.6% was esti-
mated of the time until the final decision on public funding going beyond 3 years.
The estimated probability is reduced to 2.8% at 3.5 years and 0.7% at 4 years.
Despite the existence of various long processes, a finite endpoint was estimated to
the distribution of decision times, pointing at, under the current circumstances, no
process taking longer than 1672 days (4.6 years). CONCLUSIONS: Extreme value
statistics, allowing for a more accurate modeling of the tail of survival distributions
than would be possible with standard survival techniques, is a valuable tool in
assessing the probability of long decision times associated with public funding
requests of medicines.
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FRANCE MARKET ACCESS: REVIEW OF 2011-2012 ASSESSMENTS BY
TRANSPARENCY COMMITTEE
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: In France assessments by the Transparency Committee (TC) plays a
significant role in pricing and market access of new products. TC evaluates clinical
efficacy and safety data of new interventions, and compares it to current standard
of care. TC’s assessments are made using ASMR ratings ranging from I to V (major
innovation to no improvement). The objective of this study was to understand
trends in TC’s assessments for new products approved by the EMA in 2011-2012.
METHODS: TC’s assessments for 11 products approved by the EMA during 2011-
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2012 were analyzed for their ASMR ratings. Analysis were conducted to identify
new trends and compare them for products based on their indications, compara-
tors and launch timing. RESULTS: Analysis of 2011-2012 assessments by TC shows
that majority of products (73%) received an ASMR rating of IV (minor improve-
ment). Approximately 27% of the products received an ASMR rating of III and V. A
new trend in TC’s assessment is the assignment of two ASMR ratings for one
product for different subgroups or patient line of treatment. During last one year 3
out of 11 products received two ASMR ratings. None of the products received ASMR
ratings of I and II. The products that received ASMR rating of V (no improvement)
were indicated for cardiovascular, epilepsy and bone metastases. All assessments
included analysis of intervention’s data versus one or more comparators.
CONCLUSIONS: France TC’s assessments trends show need for robust comparative
effectiveness data to obtain better ASMR ratings, which affects both pricing and
market access of new products. Future products would need subgroup analysis to
obtain high ASMR ratings for all patient populations.
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SYSTEMATIC REVIEW OF KEY ISSUES IN ENDOSCOPE REPROCESSING –
GUIDELINE ADHERENCE, HEALTH OUTCOMES AND RESOURCE USE
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OBJECTIVES: Safe endoscope reprocessing requires meticulous adherence to
guidelines. Human error is a principal cause of deficient reprocessing. Approaches
vary from fully manual processes, to semi-automatic reprocessors, or fully auto-
mated cleaner and reprocessors. We assessed key issues in endoscope reprocess-
ing related to guideline adherence, health and resource outcomes and staff burden.
METHODS: PubMed was searched from January 1, 2007 to March 7, 2012. Search
terms: ((Endoscope OR endoscopy) AND (Reprocessing OR Cleaning OR Disinfection
OR Biofilms)). Abstracts were screened by 2 independent reviewers and included
according to research areas: 1) adherence to endoscope reprocessing guidelines; 2)
endoscopy related adverse contamination outcomes and; and 3) adverse effects of
endoscope reprocessing on staff. Reference lists of key papers were searched.
RESULTS: Six studies assessed guideline adherence. Non-adherence levels varied
considerably with a trend for less developed health care systems to have poorer
adherence. For study question 2, 19 articles reported 7 infection outbreaks, 6 pseu-
do-outbreaks and 4 toxic reactions related to endoscope procedures. The majority
of events could have been prevented if standard reprocessing practices were fol-
lowed. Eight studies (1 each from Canada, Japan and US and 5 from Europe) con-
sidered the impact of device reprocessing on staff health, time, or the associated
costs. Two studies reported that manual reprocessing had a significant health
impact on staff including respiratory ailments and physical discomfort. One study
reported that in a single hospital reprocessing time was 6.2 hours longer per day
with manual vs. automated procedures; this had a resultant impact on costs.
CONCLUSIONS: Effective reprocessing is vital to ensure safe use of endoscopes.
Guideline adherence is variable, and poor standards can lead to adverse outcomes.
Manual reprocessing is associated with considerable health burdens for staff. Au-
tomated reprocessing could improve guideline adherence and reduce the burden
on staff, as well as reduce costs. Further studies in this area are warranted.
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ANALYSIS OF THE REIMBURSEMENT DECISIONS OF THE NATIONAL HEALTH
INSURANCE FUND OF HUNGARY (2007-2011)
Botlik O, Kalotai Z
Novartis Hungary, Budapest, Hungary
OBJECTIVES: Our goal was to analyze the Hungarian drug reimbursement deci-
sions - through the reimbursement of new molecular entities (NME) in the period of
2007-2011. METHODS: NME’s were collected from the official drug reimbursement
list published monthly on the website of the National Health Insurance Fund of
Hungary (NHIF). Drugs with hospital reimbursement were excluded from the anal-
ysis, as their reimbursement process differs. There are two ways to reimburse an
Rx NME in Hungary: Route A: NHIF is the final decision maker, there is no need for
legislation change. Route B: In case of e.g. new restricted indication or a new ATC4
level of a given NME, the final decison makers are, Ministry of Health & previously
Ministry of Finance, currently Ministry of Economy. In these latest cases a minis-
terial decree is published, containing the reimbursement list of NME’s. RESULTS:
Within the observed period 86 new molecules gained reimbursement from the
Drug Budget. The most NME’s gained reimbursement in 2008 (23 NME’s). A total of
33% of the products belong to two ATC categories: A and L, and most of NME’s (40%)
are fully reimbursed. 34 % of the products needed Route B to gain reimbursement.
More than half of these products (16 molecules) gained reimbursement in 2008,
however no such decision was made in 2009 and only 3 molecules have been
reimbursed in 2010 and 2011, respectively! CONCLUSIONS: The number of reim-
bursement decisions made through Route A didn’t change in this 5-year period.
However the number of Route B reimbursement decision dropped significantly
from 2008, resulting a significant market access delays for the Hungarian patients.
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OBJECTIVES: To suggest a new classification of different pharmaceutical payment
methods and to analyze the implementation of those methods in different health
care settings of IQ Partners’ Countries. This division will facilitate the comparative
analysis of the impact of different payment methods on health care costs, effi-
ciency, quality and equity. METHODS: Data on pharmaceutical payment methods
were obtained through a review of the available literature. The search included
relevant economic and medical databases, journals and books, conference mate-
rials and other projects. Different examples of payment methods were extracted
from publications (95 positions) and classified. The implementation of those meth-
ods in different countries was also described. RESULTS: The practical classification
of pharmaceutical payment methods was based on two main categories: tradi-
tional (well established and widely used) and innovative (implemented in recent
years, depending on the country). A sub-classification was also outlined, related to
the regulatory mechanisms of the methods in question: market driven, adminis-
trative regulations and market mechanisms with administrative settings (mixed).
The traditional payment methods and schemes include: “free” prices, fixed prices,
flexible prices, fixed budget, reference pricing, margins, rebate agreements, bonus
agreements and patient’s co-payment. The innovative payment methods include
price volume agreements, cross-product agreements, risk-sharing, value-based
pricing, framework agreements, cost-plus pricing, patient access schemes, portfo-
lio deals, one price per patient, disease management. The second group was sub-
sequently introduced in selected countries, including UK and US with a trend to be
used in others countries (e.g. Poland). CONCLUSIONS: Innovative payment meth-
ods allow risk-sharing both related to costs and outcomes creating an additional
platform for a dialogue between authorities and producers.
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LESSONS FROM A SURVEY OF GLOBAL HEALTH TECHNOLOGY ASSESSMENTS
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OBJECTIVES: Point-of-care (POC) testing, also called near-patient, bedside, alter-
nate-site or decentralized testing, includes all in vitro testing where conduct and
analysis occurs outside the laboratory setting (e.g., physician office, at home), and
within a short time period while the patient waits. Development of POC diagnostic
tests (POCTs) has been on the rise in recent years and promises to reduce health
care costs by reducing utilization of costly centralized laboratory-based testing, the
need for follow-up office visits by patients to review laboratory test results, and/or
sample shipment and storage. Despite the potential of POC testing, health systems
and payers have been slow to adopt and reimburse such tests. To examine key
issues influencing POCT reimbursement and market access, global health technol-
ogy assessments (HTAs) were evaluated to identify stakeholder concerns contrib-
uting to the slow penetration of POCTs. METHODS: Published global POCT HTA
recommendations were identified and reviewed to provide insights into criteria
scrutinized and concerns registered by HTA agencies. RESULTS: POCT HTAs iden-
tified included those for cardiovascular, endocrine, oncologic, pulmonary/allergic,
and infectious diseases, and those informing therapeutic or illicit drugs. In assess-
ing POCTs, agencies scrutinized criteria generally fitting into four categories of
evidence including Testing Logistics, Clinical Validity/Utility, Economic Value/
Cost, and Ethical Concerns. For Testing Logistics: agencies scrutinized test turn-
around time, platform accessibility and current penetration, required sample size,
specimen collection and transport, and result/quality tracking; Clinical Validity/
Utility: test performance (e.g., sensitivity, specificity, false positives/negatives) and
agreement with/efficacy relative to lab-based tests, and impact on provider deci-
sion-making/patient outcomes; Economic Value/Cost: cost-offsets, cost-effective-
ness, and cost-minimization; Ethical Concerns: implications of erroneous results
and privacy issues. CONCLUSIONS: POC testing approaches hold potential to re-
duce health care costs while maintaining or improving patient outcomes. Evidence
required to support POCT HTA should be considered during development of new
POCTs to increase the likelihood of achieving reimbursement and market access.
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EXPLANING DIFFERENCES IN EU5 MARKET PENETRATION LEVELS AND RATES
OF BIOSIMILARS: THE CASE OF EPOETINE, GRANULOCYTE-COLONY
STIMULATING FACTOR, AND GROWTH HORMONES
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OBJECTIVES: Biosimilars are off-patent biologicals that shall provide cost savings
and greater accessibility to biopharmaceuticals. Within the next five years, several
top-selling biologics like Herceptin, Enbrel, Humalog, are due to loose patent pro-
tection. This opens business opportunities, but little is known about the biosimilar
market. The main biosimilar product classes are biosimilars of Epoetine (EPO),
Granulocyte-Colony Stimulating Factor (G-CSF) and Growth Hormoes (GH). Market
penetration levels for these biosimilars differ substantially across Germany,
France, UK, Italy and Spain (EU5). Literature does not provide an stringent expla-
nation for these differences.We attempt to fill this gap by explaining the diverse
levels of biosimilar uptake. METHODS: We model the diffusion process of biosimi-
lars in pharmaceutical markets with a Bass diffusion model. Model parameters are
estimated from IMS Health sales data on three Biosimilar classes in the EU5 coun-
tries. The estimated model parameters differ across countries and products. To
explain these differences, we conduct several expert interviews.The theoretical
lense guiding the interviews is Rogers theory of innovations and how properties of
an innovation influence diffusion. RESULTS: We find that Germany and France
account for approximately half the biosimilars market by value and a 34% and 17%
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